Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

NCT04130516 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
BIOLOGICAL: Pembrolizumab - anti-PD-1 antibody

Sponsor

Linnaeus Therapeutics, Inc.

Collaborators

[object Object]